Literature DB >> 16882124

Lymphoma: variations in time to diagnosis and treatment.

D A Howell1, A G Smith, E Roman.   

Abstract

This study examines illness trajectories of patients with lymphoma and assesses whether UK government targets to reduce waiting time for diagnosis and treatment are achievable and appropriate. One hundred and ninety-four patients, residents in West Yorkshire, aged more than 25 years and newly diagnosed with lymphoma during 2000 were included. Data collected from interviews, primary care and hospital records were used to examine time between critical events on the illness trajectory and characteristics of patients not meeting proposed targets. Forty-two per cent of patients did not receive a hospital appointment within 2 weeks of general practitioner referral, 26% were not treated within 1 month of diagnosis and 64% were not treated within 2 months of referral. Target achievement differed by diagnostic group, and trends were seen by age and deprivation. The interval from onset of symptoms to treatment averaged more than 1 year and approximately half of this occurred before first medical contact. Results suggest that significant improvements are needed to achieve targets. Although existing targets particularly address referral and treatment intervals, these were the shortest intervals on the trajectory. Generalized targets may be inappropriate and unachievable for lymphoma as they do not consider individual disease characteristics or allow for variations in the urgency with which treatment is needed.

Entities:  

Mesh:

Year:  2006        PMID: 16882124     DOI: 10.1111/j.1365-2354.2006.00651.x

Source DB:  PubMed          Journal:  Eur J Cancer Care (Engl)        ISSN: 0961-5423            Impact factor:   2.520


  10 in total

1.  Waiting time to lymph node biopsy is dependent on referral method: don't write, phone!

Authors:  S A J Pannick; C L Ingham Clark
Journal:  Ann R Coll Surg Engl       Date:  2009-09-25       Impact factor: 1.891

2.  Diagnosing lymphoma in the shadow of an epidemic: lessons learned from the diagnostic challenges posed by the dual tuberculosis and HIV epidemics.

Authors:  Katherine Antel; Vernon Johan Louw; Gary Maartens; Jenna Oosthuizen; Estelle Verburgh
Journal:  Leuk Lymphoma       Date:  2020-09-13

3.  Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network.

Authors:  A Smith; D Howell; R Patmore; A Jack; E Roman
Journal:  Br J Cancer       Date:  2011-11-01       Impact factor: 7.640

4.  Time to diagnosis and associated costs of an outpatient vs inpatient setting in the diagnosis of lymphoma: a retrospective study of a large cohort of major lymphoma subtypes in Spain.

Authors:  Xavier Bosch; Carmen Sanclemente-Ansó; Ona Escoda; Esther Monclús; Jonathan Franco-Vanegas; Pedro Moreno; Mar Guerra-García; Neus Guasch; Alfons López-Soto
Journal:  BMC Cancer       Date:  2018-03-12       Impact factor: 4.430

5.  Rapid access clinic for unexplained lymphadenopathy and suspected malignancy: prospective analysis of 1000 patients.

Authors:  Andrea Kühnl; David Cunningham; Margaret Hutka; Clare Peckitt; Hamoun Rozati; Federica Morano; Irene Chong; Angela Gillbanks; Andrew Wotherspoon; Michelle Harris; Tracey Murray; Ian Chau
Journal:  BMC Hematol       Date:  2018-08-14

6.  The determinants and impact of diagnostic delay in lymphoma in a TB and HIV endemic setting.

Authors:  Katherine Antel; Carly Levetan; Zainab Mohamed; Vernon J Louw; Jenna Oosthuizen; Gary Maartens; Estelle Verburgh
Journal:  BMC Cancer       Date:  2019-04-25       Impact factor: 4.430

7.  The impact of structural factors on diagnostic delay in diffuse large B-cell lymphoma.

Authors:  Joanna C Zurko; Raymond C Wade; Amitkumar Mehta
Journal:  Cancer Med       Date:  2019-03-18       Impact factor: 4.452

8.  Quantifying the risk of Hodgkin lymphoma in symptomatic primary care patients aged ≥40 years: a case-control study using electronic records.

Authors:  Elizabeth A Shephard; Richard D Neal; Peter W Rose; Fiona M Walter; William T Hamilton
Journal:  Br J Gen Pract       Date:  2015-05       Impact factor: 5.386

9.  Time-to-diagnosis and symptoms of myeloma, lymphomas and leukaemias: a report from the Haematological Malignancy Research Network.

Authors:  Debra A Howell; Alexandra G Smith; Andrew Jack; Russell Patmore; Una Macleod; Emma Mironska; Eve Roman
Journal:  BMC Hematol       Date:  2013-10-31

10.  Risk factors and time to symptomatic presentation in leukaemia, lymphoma and myeloma.

Authors:  Debra A Howell; Fiona Warburton; Amanda-Jane Ramirez; Eve Roman; Alexandra G Smith; Lindsay J L Forbes
Journal:  Br J Cancer       Date:  2015-09-01       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.